about
Combined Inhibitor Free-Energy Landscape and Structural Analysis Reports on the Mannosidase Conformational CoordinateA structural and energetic model for the slow-onset inhibition of the Mycobacterium tuberculosis enoyl-ACP reductase InhA.The Role of a Novel Auxiliary Pocket in Bacterial Phenylalanyl-tRNA Synthetase DruggabilityStructural Snapshots for Mechanism-Based Inactivation of a Glycoside Hydrolase by Cyclopropyl CarbasugarsTwo-step ATP-driven opening of cohesin headStructure and stereochemistry of the base excision repair glycosylase MutY reveal a mechanism similar to retaining glycosidasesPotent inhibition of the C-P lyase nucleosidase PhnI by Immucillin-A triphosphate.Transition-state analysis of 2-O-acetyl-ADP-ribose hydrolysis by human macrodomain 1.Replacing sulfa drugs with novel DHPS inhibitorsCrystal structures of Mycobacterium tuberculosis GlgE and complexes with non-covalent inhibitors.An active site-tail interaction in the structure of hexahistidine-tagged Thermoplasma acidophilum citrate synthase.Kinetic isotope effects reveal early transition state of protein lysine methyltransferase SET8.Modulating Enzyme Catalysis through Mutations Designed to Alter Rapid Protein Dynamics.Anion-π EnzymesComparing the energy landscapes for native folding and aggregation of PrP.Recent Advances in the Discovery of Norovirus Therapeutics.How quickly can a β-hairpin fold from its transition state?Medicinal chemistry of fluorinated cyclic and acyclic nucleoside phosphonates.Dissecting conformational contributions to glycosidase catalysis and inhibition.Active transporters as enzymes: an energetic framework applied to major facilitator superfamily and ABC importer systems.Development of Small-Molecule Antivirals for Ebola.Influence of Equatorial CH⋅⋅⋅O Interactions on Secondary Kinetic Isotope Effects for Methyl TransferH3K36 methyltransferases as cancer drug targets: rationale and perspectives for inhibitor developmentRepair of 8-oxoG:A mismatches by the MUTYH glycosylase: Mechanism, metals and medicine.The slow dissociation rate of K-1602 contributes to the enhanced inhibitory activity of this novel alkyl-aryl-bearing fluoroketolide.Cation Clock Reactions for the Determination of Relative Reaction Kinetics in Glycosylation Reactions: Applications to Gluco- and Mannopyranosyl Sulfoxide and Trichloroacetimidate Type Donors.The future of drug discovery: enabling technologies for enhancing lead characterization and profiling therapeutic potential.Immucillins in Infectious Diseases.The mechanism and high-free-energy transition state of lac repressor-lac operator interaction.Visualization of the Reaction Trajectory and Transition State in a Hydrolytic Reaction Catalyzed by a Metalloenzyme.An Immucillin-Based Transition-State-Analogous Inhibitor of tRNA-Guanine Transglycosylase (TGT).Synthesis, Reactivity, Functionalization, and ADMET Properties of Silicon-Containing Nitrogen Heterocycles.
P2860
Q27680888-F5EADD38-4680-4BB8-B69F-F5935333E490Q27681724-10D8A2FD-2D38-42D8-AAC8-75F360CC6247Q27684359-1EC740FA-2E43-4EBD-A216-016252C45370Q28770307-F004957B-587D-45E2-98FE-4696E28A81D1Q30855484-22CB1E61-F719-4424-9ED8-4B22134C7C03Q31032369-ACE05B7E-5892-44E1-BB8A-FB9DC82514C9Q34038463-BB321B44-A3EB-462A-8949-ED47B423ED67Q34361141-7BBD0D34-44FC-488A-BB2E-1FD06B916792Q34823402-4F294E02-33B6-47F0-B73A-FD947F332659Q35922181-85190112-C8C0-4CD6-902E-5F508310004DQ36148187-4CD39181-83DE-480A-8B2A-217E8B07792EQ36219705-17A388BC-05C3-4930-AFA1-60F0E2DD6BC0Q36693213-FC5AC4CF-2062-4EF9-A1B5-954E9EA54D3BQ37035262-C478A2ED-435C-492B-91E1-FC6461986E75Q37167847-01C073D5-D8A3-40E4-903A-94E54086977CQ37517465-33BD0A48-66F5-43D6-A2BE-8621DBE2791FQ37671331-3D7F3609-FB72-4C17-9D83-CE33D4E9DEDAQ38124799-C0D4F79E-014D-4347-B5BE-01B6D48D8CDAQ38228725-4D0F4C53-1638-4C0A-80A6-09192D5BCD48Q38300028-3A71B220-A373-449A-8460-2410415F3B64Q38546746-1A191C83-9DDC-4BC6-9FE3-50E9D26ED63DQ38670234-B7E9A55F-A1CC-4B24-8D5B-626F513DDCEDQ38829055-7E0272E3-94E6-4E22-B88E-6CAC5B85EDC5Q39087831-AD2C2057-A822-40A4-9DA0-AE5476CC617FQ41163904-79DC4A11-E813-4E5C-AB20-75386725BA73Q42734177-BA3D6860-341C-48E6-87B9-FE6F67E8989DQ44441472-BBB399A1-E3AD-4615-B3E9-00C8ED105678Q46259033-ABA480F0-902C-44D2-91C6-4402E8C44AB7Q47111357-F6C19A56-982E-41F7-8FD4-7CFAE82A690AQ48162804-A9C3D747-365F-42DC-9389-F9018778FD5AQ53186937-637478A1-F475-4FFF-B524-6B2B1C606454Q55361717-49C33291-EBCD-46DD-A0B3-C4DA059E59AB
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Transition States, analogues, and drug development.
@en
type
label
Transition States, analogues, and drug development.
@en
prefLabel
Transition States, analogues, and drug development.
@en
P2860
P356
P1433
P1476
Transition States, analogues, and drug development.
@en
P2093
Vern L Schramm
P2860
P356
10.1021/CB300631K
P577
2013-01-04T00:00:00Z